Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 361 to 370 of 441 total matches.
Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
The Medical Letter on Drugs and Therapeutics • Jan 19, 2026 (Issue 1746)
days; they are less likely to be fatal now that effective
treatment is available.
Uncontrolled ...
Donidalorsen (Dawnzera – Ionis), a subcutaneously
injected prekallikrein-directed antisense oligonucleotide,
has been approved by the FDA for prevention
of hereditary angioedema (HAE) attacks in patients
≥12 years old. It is the first RNA-targeted drug to be
approved in the US for this indication.
Med Lett Drugs Ther. 2026 Jan 19;68(1746):12-4 doi:10.58347/tml.2026.1746c | Show Introduction Hide Introduction
Sarecycline (Seysara) - Another Oral Tetracycline for Acne
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
), a new oral
tetracycline antibiotic, has been approved by the FDA
for once-daily treatment ...
Sarecycline (Seysara — Allergan), a new oral
tetracycline antibiotic, has been approved by the FDA
for once-daily treatment of inflammatory lesions of
non-nodular moderate to severe acne in patients ≥9
years old.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
shippers as described in the
guidelines packed in the containers, with dry ice periodically
replenished ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
:1500.
2. In addition to standard treatment.
3. Standard treatment was based on local guidelines ...
Evolocumab (Repatha – Amgen), a subcutaneously
injected PCSK9 inhibitor, has been approved by the
FDA as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional
lowering of LDL-cholesterol (LDL-C). It was also
approved as an adjunct to diet and other LDL-lowering
therapies in patients with homozygous familial
hypercholesterolemia (HoFH) who require additional
lowering of LDL-C. Evolocumab is the second PCSK9
inhibitor to be approved in the...
Jatenzo - An Oral Testosterone for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated ...
An oral formulation of testosterone undecanoate
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated
with a deficiency of endogenous testosterone, such as
Klinefelter syndrome, orchiectomy, toxic damage from
chemotherapy or alcohol, or pituitary-hypothalamic
injury from tumors, trauma, or radiation. Jatenzo is
not approved for treatment of low testosterone levels
solely due to aging. It is the first oral testosterone
formulation to be approved in the US.
Clopidogrel (Plavix) Revisited
The Medical Letter on Drugs and Therapeutics • Apr 10, 2006 (Issue 1232)
that treatment with clopidogrel in addition to aspirin significantly
lowered the risk of CV death, MI or urgent ...
Clopidogrel (Plavix - Sanofi-Aventis and Bristol-Myers Squibb), an oral thienopyridine that inhibits platelet aggregation, is now being advertised directly to the public on television. Clopidogrel is approved by the FDA for secondary prevention of myocardial infarction (MI), stroke and other vascular events and for use in patients with acute coronary syndrome (unstable angina or non-ST-elevation MI), including those undergoing angioplasty. It is used off-label for patients with ST-elevation acute MI
Safety of Smoking Cessation Drugs
The Medical Letter on Drugs and Therapeutics • Aug 24, 2009 (Issue 1319)
tobacco use and dependence: 2008
Update. Clinical Practice Guideline. Rockville, MD: US Department ...
The most effective drugs available for treatment of tobacco dependence are bupropion (Zyban, and others and varenicline (Chantix). The FDA recently ordered the manufacturers of both to add boxed warnings about the risk of psychiatric symptoms and suicide to their prescribing information (FDA Alert, 7/1/2009).
Who Should Take Vitamin Supplements?
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
. (US Department of Agriculture Dietary Guidelines for Americans
2010 found at http://www.cnpp.usda.gov ...
Many patients ask their healthcare providers whether
they should take vitamins. Since the last Medical Letter
article on this subject, more data have become available
on the benefits and risks of taking vitamins.
Clozapine
The Medical Letter on Drugs and Therapeutics • Feb 19, 1993 (Issue 890)
who could
not tolerate the extrapyramidal effects of other antipsychotic drugs. In the treatment ...
Clozapine (Clozaril - Sandoz), an antipsychotic drug, was first marketed in the USA three years ago (Medical Letter, 32:3, 1990). Because of its hematological toxicity, the US Food and Drug Administration approved the drug only for patients with schizophrenia who cannot tolerate or do not respond to standard antipsychotic drugs.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
and are frequently
prescribed for treatment of moderate to severe
disease, but guidelines generally discourage ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
